Industry News

Dr Reddy's growth tonic isn't working [Mint, New Delhi]
Adani Transmission Ltd. The firm plans to raise about $400 million through a dollar bond issue and has mandated seven banks to market it to offshore investors, according to two bankers aware of..."/>
Adani Transmission latest to tap offshore bonds as investor interest revives [Mint, New Delhi]
Inovio Pharmaceuticals' experimental vaccine to combat the Zika virus, the Plymouth meeting biotech company said Tuesday. Inovio is developing its Zika vaccine with partner GeneOne Life Science in South Korea. Food and Drug Administration and Health Canada's Health Products and Food Branch have approved early-stage tests in 40 healthy adults, the company said."/>
Montco company doses first volunteer with experimental Zika vaccine [The Philadelphia Inquirer]
M and A Navigator: Deal pipeline –26 July
Insmed Incorporated. Investors who purchased or otherwise acquired shares between March 18, 2013 and June 8, 2016, are encouraged to contact the firm in advance of the September 13, 2016 lead plaintiff motion deadline.. If you are a shareholder who suffered a loss during the Class Period, click here to participate."/>
SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Insmed Incorporated and Encourages Investors with Losses to Contact the Firm
Fiesta Restaurant Group Inc. will replace ExamWorks Group Inc. in the S&P SmallCap 600 after the close of trading on Wednesday, July 27. Leonard Green& Partners, L.P is acquiring ExamWorks Group in a deal expected to be completed on or about that date. Maiden Holdings Ltd. will replace Tumi Holdings Inc. in the S&P SmallCap 600 after the close of trading on Monday, August 1."/>
Fiesta Restaurant Group and Maiden Holdings to Join the S&P SmallCap 600
Ekso Bionics Holdings, Inc., a robotic exoskeleton company, today announced that it will release financial and business results for the second quarter 2016 after the close of trading on Thursday, July 28, 2016. The Company’ s management team will host a corresponding conference call beginning at 1:30 p.m. PT/ 4:30 p.m. ET to discuss the financial results and recent business developments.. Investors interested in listening to the conference call may..."/>
Ekso Bionics to Report Second Quarter 2016 Financial Results on July 28, 2016
CytRx Corporation. Investors who purchased or otherwise acquired shares between November 18, 2014 and July 11, 2016 inclusive, are encouraged to contact the Firm prior to the September 23, 2016 lead plaintiff motion deadline.. If you purchased shares of CytRx during the Class Period, please contact Joon M. Khang, Esquire, of Khang& Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by..."/>
IMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit Against CytRx Corporation and Reminds Investors With Losses to Contact the Firm
BIND Therapeutics, Inc., a biotechnology company developing targeted and programmable therapeutics called ACCURINS ®, today announced that Pfizer Inc. prevailed at a Section 363 auction to purchase substantially all of BIND’ s assets. The winning bid of $40 million, subject to U.S. Bankruptcy Court approval for which a hearing is scheduled to take place on July 27, 2016, was selected as the highest and best bid."/>
BIND Therapeutics Determines Pfizer’s $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND’s Assets
Relypsa, Inc. have entered into a definitive agreement under which Galenica will acquire Relypsa, the companies said. Relypsa is a biopharmaceutical company based in Redwood City, Calif., with more than 400 employees. The company, founded in 2007, is focused on the discovery, development and commercialisation of polymeric medicines for patients with conditions that can be addressed in the gastrointestinal..."/>
Galenica to Acquire US GI Drugmaker Relypsa for USD 1.53bn
Teva Pharmaceutical Industries Ltd. has priced a debt offering by its special purpose finance subsidiary Teva Pharmaceutical Finance Netherlands IV B.V., the company said. The offering consists of aCHF 300 m tranche of 0.125% fixed rate senior notes maturing in 2018; CHF 350 m of 0.500% fixed rate senior notes maturing in 2022; and CHF 350 m of 1.000% fixed rate senior notes maturing in 2025.. These notes are in addition to the..."/>
Teva Announces Pricing of Additional CHF 1bn of Senior Notes; Will Use for Actavis Generics Acquisition
Aetna and Humana Inc. plan to vigorously defend the companies' pending merger in response to a US Department of Justice lawsuit seeking to block the transaction, the companies said. Last July, Aetna agreed acquire all outstanding shares of Humana for a combination of cash and stock valued at USD 48 bn. The combination brings together Humana's Medicare Advantage business with Aetna's portfolio and commercial capabilities to create a..."/>
Aetna and Humana Vow to “Vigorously Defend” Merger Following US DOJ Block
Parnell Pharmaceuticals Holdings Ltd., a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, announced today that it will report financial results for the six months ended June 30, 2016 on August 4, 2016 at 7:00 am ET.. Management will host a conference call on August 4, 2016 at 8 am ET to discuss financial results and answer questions. Investors and analysts may..."/>
Parnell to Report Financial Results for the Six Months Ended June 30, 2016 on August 4, 2016
Psychemedics Corporation today announced second quarter financial results for the period ended June 30, 2016. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of August 5, 2016 to be paid on August 15, 2016. This will be the Company's 80 th consecutive quarterly dividend."/>
Psychemedics Corporation Announces Record Revenues And Earnings
Globus Medical, Inc., a leading musculoskeletal implant manufacturer, today announced that it has entered into an agreement to acquire the international operations and distribution channels of Alphatec Holdings, Inc., a publicly traded medical devices company for $80.0 million in cash, subject to certain closing adjustments. Globus Medical also agreed to extend a 5- year senior secured credit facility of up to $30.0 million to Alphatec to support..."/>
Globus Medical Announces the Acquisition of Alphatec’s International Business
GeneNews Limited provided an update today on its financing activities.. Pursuant to its capital commitment agreement with GEM Global Yield Fund LLC SCS, GeneNews has made its first draw down under the Capital Commitment in the amount of CAD $51,803. In connection with the draw down, 338,702 common shares were issued to GEM at a price per share of CAD $0.153, which is equal to a 10 per cent..."/>
GeneNews Provides Financing Update
Globus Medical, Inc., a leading musculoskeletal implant manufacturer, today announced its financial results for the second quarter ended June 30, 2016.. Worldwide sales increased 2.9% as reported to $137.5 million, or 3.1% on a constant currency basis Second quarter net income increased 7.3% to $25.8 million, or 18.8% of sales Diluted earnings per share increased 6.9% to $0.27 Non-GAAP diluted EPS increased 10.6% to $0.29 Non-GAAP Adjusted EBITDA was..."/>
Globus Medical Reports Second Quarter 2016 Results
Alphatec Holdings, Inc., the parent company of Alphatec Spine, Inc., a global provider of spinal fusion technologies, announced today that it has entered into a definitive agreement with Globus Medical, a leading musculoskeletal implant manufacturer, whereby Globus will acquire Alphatec’ s international operations and distribution channel for a purchase price of $80 million. As part of the transaction, Globus has also agreed to provide Alphatec a..."/>
Alphatec Holdings Announces Sale of International Business to Globus Medical
Universal Health Services, Inc. announced today that its reported net income attributable to UHS was $185.6 million, or $1.89 per diluted share, during the second quarter of 2016 as compared to $182.2 million, or $1.80 per diluted share, during the comparable quarter of 2015. Net revenues increased 6.8% to $2.43 billion during the second quarter of 2016 as compared to $2.28 billion during the second quarter of 2015.."/>
Universal Health Services, Inc. Reports 2016 Second Quarter Financial Results
VIVUS, Inc. today announced that it will report financial results and provide a business update for the second quarter of 2016 after the NASDAQ Market closes on Thursday, August 4, 2016. The company will conduct a conference call and an audio webcast at 4:30 pm EST the same day. Date: August 4, 2016 Time: 4:30 PM EST. Dial in: 1 224-357-2386 Dial in: 1 877-359-2916 Audience Passcode: 494 658 37."/>
VIVUS Announces Date of 2016 Second Quarter Business Update and Financial Results Teleconference
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it will release second quarter financial results on Tuesday, August 2, 2016 after the market closes. Regulus will host a conference call and webcast on August 2, 2016 at 5:00 p.m. Eastern Time to discuss second quarter financial results and provide a general business update."/>
Regulus to Release Second Quarter Financial Results on August 2, 2016
Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2016.. Sales grew 23.1% to $759.3 million; underlying 1 sales were up 21% Global Transcatheter Heart Valve Therapy sales grew 48.7%; underlying grew 45% U.S. THVT sales were up 71.5%; underlying grew 66% GAAP EPS was $0.58, an increase..."/>
Edwards Lifesciences Reports Second Quarter Results
BioTelemetry, Inc. will release its second quarter 2016 earnings on Tuesday, August 2, 2016 at 4:00 PM Eastern Time.. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Tuesday, August 2, 2016. The broadcast will be available through the investor information section of the BioTelemetry website"/>
BioTelemetry, Inc. to Release Second Quarter 2016 Earnings Results on August 2, 2016

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials752 Articles
Information Technology670 Articles
Consumer Discretionary618 Articles
Industrials490 Articles
Health Care433 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at